论文部分内容阅读
目的观察罗格列酮联合二甲双胍对大鼠非酒精性脂肪肝(NAFLD)的防治作用。方法42只SD大鼠随机分为三组,C组给予正常饮食作为空白对照;A、B组给予高脂饮食12周,A组在高脂饮食同时给予罗格列酮和二甲双胍治疗。12周后处死大鼠,称量大鼠体重和肝脏湿重,检测血糖、血脂、肝功能,并行肝组织病理学检查和肝脏脂肪测定。结果B组体重、肝湿重、肝指数(肝湿重/体重×100%)均升高(P<0.01);A组肝湿重、肝指数低于B组(P<0.01)。B组血糖较C组增加(P<0.05);B组存在脂代谢紊乱,A组脂代谢紊乱明显改善。B组有程度不同肝细胞脂肪变性,脂变程度以中、重度为主;A组肝细胞脂肪变性明显轻于B组(P<0.01);A组肝脏甘油三酯含量明显低于B组(P<0.01)。结论罗格列酮联合二甲双胍可明显改善NAFLD大鼠的血脂紊乱和肝脏脂肪变性。
Objective To observe the preventive and therapeutic effects of rosiglitazone and metformin on nonalcoholic fatty liver disease (NAFLD) in rats. Methods Forty-two SD rats were randomly divided into three groups. Group C was given normal diet as blank control. Group A and B were fed with high-fat diet for 12 weeks. Group A was treated with rosiglitazone and metformin on high fat diet. After 12 weeks, the rats were sacrificed and the body weight and wet weight of the liver were weighed. Blood glucose, blood lipids and liver function were measured. Liver histopathology and liver fat were measured. Results The body weight, liver wet weight and liver index (wet weight of liver / body weight × 100%) of group B were all increased (P <0.01). The wet weight of liver in group A was lower than that of group B (P <0.01). The blood glucose of group B was higher than that of group C (P <0.05). The lipid metabolism disorder was found in group B, and the disturbance of lipid metabolism in group A was significantly improved. In group B, there was degree of hepatocellular steatosis, and the degree of lipid change was moderate and severe. The fatty degeneration of hepatocytes in group A was lighter than that in group B (P <0.01); The level of hepatic triglyceride in group A was significantly lower than that in group B P <0.01). Conclusions Rosiglitazone combined with metformin can significantly improve the dyslipidemia and hepatic steatosis in NAFLD rats.